REGN had 5 presentations at the Experimental Biology Meeting of the Federation of American Societies of Experimental Biology (FASEB) in Washington, D.C. (www.fasb.org) The first two are posters and the last three are symposia. An abstract is available for the 5th one.
Jason
----------------------------
Title/Author/Institute
1
Title: TRANSGENIC OVEREXPRESSION OF VEGF AND ANGIOPOIETIN-1 INDUCE THE PROLIFERATION
OF VESSELS OF DIFFERENT SIZE.
Authors: K.M. SMITH, G. THURSTON, C. SURI, T.J. MURPHY, G.D. YANCOPOULOS AND D.M.
MCDONALD.
Inst: UCSF AND REGENERON PHARMACEUT, TARRYTOWN, NY.
Session Title:ANGIOGENESIS/MICROVASCULAR REMODELING
2
Title: SKIN MICROVASCULATURE IN MICE THAT TRANSGENICALLY OVEREXPRESS ANGIOPOIETIN-1
IS RESISTANT TO INFLAMMATORY STIMULI.
Authors: G. THURSTON, C. SURI, K.M. SMITH, G.D. YANCOPOULOS AND D.M. MCDONALD.
Inst: UCSF AND REGENERON PHARMACEUT., TARRYTOWN, NY.
Session Title:ANGIOGENESIS/MICROVASCULAR REMODELING
3
Title: ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 INDUCE ANGIOGENESIS IN A FIBRIN-MATRIX MODEL
IN VITRO.
Authors: K. TEICHERT-KULISZEWSKA, N. JONES, A.I.M. CAMPBELL, S. BABAEI, L.S. ROTH, M.P.
BENDECK, K. ALITALO, D.J. DUMONT, G.D. YANCOPOULOS AND D.J. STEWART.
Inst: ST. MICHAEL'S HOSP., UNIV. OF TORONTO SUNNYBROOK HLTH. SCI. CTR., UNIV. OF HELSINKI
AND REGENERON PHARMACEUT. INC.
Session Title:TISSUE REMODELING IN ANGIOGENESIS
4
Title: ANGIOPOIETINS AND VASCULAR DEVELOPMENT.
Authors: G.D. YANCOPOULOS.
Inst: REGENERON PHARMACEUT. INC.
Session Title:VASCULAR DEVELOPMENT AND PATTERNING
5
Title: THE ANGIOPOIETINS: CRITICAL ROLES DURING NORMAL AND PATHOLOGIC ANGIOGENESIS.
Authors: G.D. YANCOPOULOS.
Inst: REGENERON PHARMACEUT. INC., TARRYTOWN, NY.
Session Title:EXTRACELLULAR MATRIX AND SIGNALING
---------------------------------
Program Number: 632.1
The Angiopoietins: Critical Roles During Normal and Pathologic Angiogenesis George D. Yancopoulos. Regeneron
Pharmaceuticals, Inc.
We have recently identified a family of growth factors, the Angiopoietins, that join the members of the vascular endothelial growth
factor (VEGF) family as the only known growth factors largely specific for vascular endothelial cells. For both the Angiopoietins and
the VEGFs, this specificity is due to the fact that these factors act via a largely endothelial cell-specific family of receptor tyrosine
kinases; the receptors bound by the Angiopoietins are known as the TIE receptors. Indicating that tight regulation of the TIE receptors
is crucial for normal angiogenesis, the Angiopoietins provide the first example of positive and negative regulators acting on the same
receptor tyrosine kinase in vertebrates: Angiopoietin-1 (Ang-1) is a naturally-occurring activator of the TIE receptors, while
Angiopoietin-2 (Ang-2) is a naturally-occurring antagonist. Gene knockout studies in mice initially suggested that while VEGF is
necessary for early stages of vascular development, Angiopoietin-1 (Ang-1) is required for later stages of vascular remodeling. More
recent studies confirm the notion that the Angiopoietins and the VEGFs work together in complementary and coordinated fashion, not
only during development but in the initiation of both normal and pathological (e.g. as in tumors) neovascularization states in the adult.
Preliminary investigations indicate that the Ang-1 and Ang-2 can be used to positively and negatively regulate blood vessel growth in
vivo, suggesting that the Angiopoietins may be exciting candidates to be considered for the therapeutic manipulation of angiogenesis. |
